| pubmed-article:9406118 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9406118 | lifeskim:mentions | umls-concept:C0001992 | lld:lifeskim |
| pubmed-article:9406118 | lifeskim:mentions | umls-concept:C0028351 | lld:lifeskim |
| pubmed-article:9406118 | lifeskim:mentions | umls-concept:C0025519 | lld:lifeskim |
| pubmed-article:9406118 | lifeskim:mentions | umls-concept:C0521390 | lld:lifeskim |
| pubmed-article:9406118 | lifeskim:mentions | umls-concept:C0002003 | lld:lifeskim |
| pubmed-article:9406118 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:9406118 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:9406118 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:9406118 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:9406118 | pubmed:dateCreated | 1998-1-30 | lld:pubmed |
| pubmed-article:9406118 | pubmed:abstractText | After norepinephrine (NE) is deaminated by monoamine oxidase (MAO), the aldehyde formed is either metabolized to 3,4-dihydroxy-mandelic acid (DHMA) by aldehyde dehydrogenase or is converted to 3,4-dihydroxyphenylglycol (DHPG) by aldehyde or aldose reductase. The present study examined the effects of inhibition of aldehyde and aldose reductase on production of DHPG and DHMA in rats. Mean (+/- S.E.) baseline plasma concentrations of DHPG (4.73 +/- 0.21 pmol/ml) were 60-fold higher than those of DHMA (0.08 +/- 0.01 pmol/ml). Inhibition of aldose and aldehyde reductase reduced plasma DHPG concentrations to 1.88 +/- 0.14 pmol/ml and increased plasma DHMA to 4.43 +/- 0.29 pmol/ml; additional inhibition of MAO reduced plasma DHPG to 0.16 +/- 0.06 pmol/ml and DHMA to 0.19 +/- 0.02 pmol/ml. Inhibition of aldehyde and aldose reductase also increased brain tissue levels of DHMA from 8 +/- 2 to 384 +/- 47 pmol/g and decreased levels of DHPG from 70 +/- 9 to 44 +/- 5 pmol/g. The results show that DHMA is normally a minor metabolite of NE, but becomes a major metabolite after aldehyde/aldose reductase inhibition. | lld:pubmed |
| pubmed-article:9406118 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9406118 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9406118 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9406118 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9406118 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9406118 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9406118 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9406118 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9406118 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9406118 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9406118 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9406118 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9406118 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:9406118 | pubmed:issn | 0165-1838 | lld:pubmed |
| pubmed-article:9406118 | pubmed:author | pubmed-author:KawamuraMM | lld:pubmed |
| pubmed-article:9406118 | pubmed:author | pubmed-author:SatoSS | lld:pubmed |
| pubmed-article:9406118 | pubmed:author | pubmed-author:LORCYGG | lld:pubmed |
| pubmed-article:9406118 | pubmed:author | pubmed-author:KadorP FPF | lld:pubmed |
| pubmed-article:9406118 | pubmed:author | pubmed-author:EisenhoferGG | lld:pubmed |
| pubmed-article:9406118 | pubmed:author | pubmed-author:TjurminaOO | lld:pubmed |
| pubmed-article:9406118 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9406118 | pubmed:day | 13 | lld:pubmed |
| pubmed-article:9406118 | pubmed:volume | 66 | lld:pubmed |
| pubmed-article:9406118 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9406118 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9406118 | pubmed:pagination | 145-8 | lld:pubmed |
| pubmed-article:9406118 | pubmed:dateRevised | 2003-11-14 | lld:pubmed |
| pubmed-article:9406118 | pubmed:meshHeading | pubmed-meshheading:9406118-... | lld:pubmed |
| pubmed-article:9406118 | pubmed:meshHeading | pubmed-meshheading:9406118-... | lld:pubmed |
| pubmed-article:9406118 | pubmed:meshHeading | pubmed-meshheading:9406118-... | lld:pubmed |
| pubmed-article:9406118 | pubmed:meshHeading | pubmed-meshheading:9406118-... | lld:pubmed |
| pubmed-article:9406118 | pubmed:meshHeading | pubmed-meshheading:9406118-... | lld:pubmed |
| pubmed-article:9406118 | pubmed:meshHeading | pubmed-meshheading:9406118-... | lld:pubmed |
| pubmed-article:9406118 | pubmed:meshHeading | pubmed-meshheading:9406118-... | lld:pubmed |
| pubmed-article:9406118 | pubmed:meshHeading | pubmed-meshheading:9406118-... | lld:pubmed |
| pubmed-article:9406118 | pubmed:meshHeading | pubmed-meshheading:9406118-... | lld:pubmed |
| pubmed-article:9406118 | pubmed:meshHeading | pubmed-meshheading:9406118-... | lld:pubmed |
| pubmed-article:9406118 | pubmed:meshHeading | pubmed-meshheading:9406118-... | lld:pubmed |
| pubmed-article:9406118 | pubmed:meshHeading | pubmed-meshheading:9406118-... | lld:pubmed |
| pubmed-article:9406118 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9406118 | pubmed:articleTitle | Effects of aldehyde/aldose reductase inhibition on neuronal metabolism of norepinephrine. | lld:pubmed |
| pubmed-article:9406118 | pubmed:affiliation | Clinical Neuroscience Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA. | lld:pubmed |
| pubmed-article:9406118 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9406118 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9406118 | lld:pubmed |
